XFOR
X4 Pharmaceuticals, Inc
NASDAQ · Healthcare · Biotechnology · US
$3.24
+2.21%Nov 4, 2026, 21:15 UTC
X4 Pharmaceuticals, Inc said its 4WARD Phase 3 chronic neutropenia trial is expected to reach target enrollment in the fourth quarter of 2026.
Source:Nov 4, 2026, 21:15 UTC
X4 Pharmaceuticals, Inc reported its third-quarter 2026 financial results.
Source:Nov 3, 2026, 16:36 UTC
Inovio Pharmaceuticals, Aquestive Therapeutics, X4 Pharmaceuticals and Jazz Pharmaceuticals saw unusually high options volume.
Source:Oct 8, 2026, 11:00 UTC
X4 Pharmaceuticals, Inc entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior loan agreement.
Source:Aug 6, 2026, 20:15 UTC
X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.
Source:Jul 1, 2026, 11:00 UTC
X4 Pharmaceuticals appointed Kelly Gold to its Board of Directors as an independent director and member of the Audit Committee, effective July 1, 2026.
Source: